Sobi and Innate Pharma partner to accelerate lacutamab development in T-cell lymphoma
Executive summary: Sobi and Innate Pharma entered a strategic partnership on August 10, 2026, to license and develop lacutamab for T-cell lymphoma, with plans to initiate the TELLOMAK-3 confirmatory trial. The partnership advances a promising immunotherapy for a difficult-to-treat cancer with limited options, potentially accelerating regulatory pathways and expanding Sobi’s presence in oncology beyond rare diseases.
Who is involved: Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (listed on Euronext Paris and NASDAQ), with Sobi gaining licensing rights and Innate receiving development and commercialization support.
Likely next: Initiation of the TELLOMAK-3 trial in the second half of 2026, followed by interim data readouts in 2027 and potential regulatory submissions based on efficacy and safety outcomes.
Swedish Orphan Biovitrum (Sobi) and Innate Pharma have announced a strategic partnership to license and develop lacutamab, an anti-KIR3DL2 antibody, for the treatment of T-cell lymphoma. The collaboration aims to initiate the TELLOMAK-3 confirmatory trial, building on prior clinical activity observed in relapsed/refractory peripheral T-cell lymphomas. This deal expands Sobi’s oncology portfolio beyond its traditional focus on rare diseases and hematology, while providing Innate Pharma with upstream funding and commercialization support for a promising asset in a high-unmet-need oncology area.
What's next — scenarios
Clinical Success and Portfolio Diversification (40%)
Sobi successfully transitions into a major oncology player, justifying the premium paid for lacutamab.
- Positive interim readout from TELLOMAK-3 trial
- FDA Fast Track designation for lacutamab
Regulatory Hurdle/Delayed Approval (40%)
Capital is tied up in R&D with no immediate revenue stream, straining Innate Pharma's cash runway.
- Clinical trial delay exceeding 6 months
- Request for additional safety data from EMA/FDA
Commercialization Failure/Niche Market Limitation (20%)
The drug hits the market but fails to gain significant market share due to existing standard-of-care competition.
- Low uptake in early post-marketing surveillance
- Emergence of a superior competing T-cell therapy
What to watch
- TELLOMAK-3 trial enrollment updates (next 90 days)
- Sobi quarterly R&D expenditure reporting (next 60 days)
- Innate Pharma cash runway/burn rate announcements (next 90 days)
Timeline
- — Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma (PR Newswire)
Analysis — what this means
Likely next events
- TELLOMAK-3 trial initiation expected H2 2026
- Interim efficacy data anticipated by mid-2027
- Potential regulatory engagement with EMA/FDA in late 2027 if primary endpoints met
Sectors affected
- Oncology therapeutics
- T-cell lymphoma treatment
- Biotechnology partnerships
Regulatory implications
- Partnership may accelerate FDA/EMA review via potential breakthrough therapy designation
- Commercialization rights negotiation will influence pricing and market access strategies in EU and US
- Post-marketing commitments likely required for long-term safety monitoring in rare T-cell populations
Historical parallels
- Similar to Seattle Genetics’ 2011 ADCETRIS (brentuximab vedotin) partnership approach in Hodgkin lymphoma
- Mirrors Roche’s 2014 early collaboration with GlycoArt on glyco-engineered antibodies, later leading to GA101 (obinutuzumab) approval
- Analogous to Innate Pharma’s 2020 partnership with AstraZeneca on monalizumab, which advanced to Phase III in head and neck cancer
Key entities
Sources
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma — PR Newswire
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma — PR Newswire